Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma

Haematologica

Volumn 100, Issue 6, 2015, Pages 834-841

  Bordini, Jessica ^a   Bertilaccio, Maria Teresa Sabrina ^a   Ponzoni, Maurilio ^a   Fermo, Isabella ^a   Chesi, Marta ^b   Leif Bergsagel, P ^b   Camaschella, Clara ^a,c   Campanella, Alessandro ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MAYO CLINIC   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; ERYTHROPOIETIN; FAS LIGAND; HEPCIDIN; IRON;

ANEMIA; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; BONE MARROW CELL; DISEASE COURSE; ERYTHROBLAST; ERYTHROID PRECURSOR CELL; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HOMEOSTASIS; INFLAMMATION; IRON RESTRICTION; MALE; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; PROTEIN ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ANEMIA; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; ERYTHROBLASTS; FEMALE; IRON; MALE; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; TUMOR MICROENVIRONMENT;

EID: 84930510072     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118000     Document Type: Article

References (26)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
3. Musto P, Falcone A, D’Arena G. Clinical results of recombinant erythropoietin in transfusiondependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Hematol. 1997;58:314-319.
4. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13-19.
5. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861-1865.
6. Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: Role in the pathogenesis of anemia and disease progression. Blood. 2001;97(5):1155-1164.
7. Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: A major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002;99(4):1305-1313.
8. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008; 14(11):3262-3267.
9. Katodritou E, Ganz T, Terpos E, et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol. 2009;84(8):524-526.
10. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA. 2005;102(5):1324-1328.
11. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009;1790(7):682-693.
12. Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116(18):3635-3644.
13. Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111(4):2392-2399.
14. Bruns I, Cadeddu RP, Brueckmann I, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood. 2012;120(13):2620-2630.
15. Chesi M, Robbiani DF, Sebag M, et al. AIDdependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180.
16. Liu J, Zhang J, Ginzburg Y, et al. Quantitative analysis of murine terminal erythroid differentiation in vivo: Novel method to study normal and disordered erythropoiesis. Blood. 2013;121(8):e43-49.
17. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10): 1011-1023.
18. Affer M, Chesi M, Chen WD, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly superenhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014; 28(8):1725-1735.
19. Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood. 2012; 120(2):376-385.
20. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433.
21. Kim A, Rivera S, Shprung D et al. Mouse models of anemia of cancer. PLoS One. 2014;9(3):e93283.
22. Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 2012;26 Suppl 1:S12-15.
23. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia. 2004;18 (7):1176-1199.
24. Wu KJ, Polack A, Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science. 1999;283(5402):676-679.
25. Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica. 2013;98(11):1667-1676.
26. Campanella A, Santambrogio P, Fontana F, et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica. 2013;98(6):971-979.